The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

Completed · Phase 2

Conditions studied: Cytomegalovirus Retinitis, HIV Infections

In brief

To determine whether cidofovir (HPMPC) therapy administered by intravenous infusion can extend the time to progression of peripheral cytomegalovirus (CMV) retinitis in AIDS patients. To evaluate the safety and tolerance of HPMPC therapy when administered by intravenous infusion in AIDS patients with CMV retinitis that is not immediately sight-threatening. To evaluate the virologic effects of intravenous HPMPC therapy on CMV shedding in urine, blood, and/or semen. To evaluate the impact of HPMPC therapy on visual acuity.

Key facts

Study ID

NCT00002437

Run by

Gilead Sciences

People needed

48

Last updated by the study team

2005-06-24

Who can join

Age: 13 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Concurrent Medication:
• Allowed:
• Antiretroviral agents.
• Oral trimethoprim/sulfamethoxazole.
• Aerosolized pentamidine.
• Dapsone.
• Fluconazole.
• Rifabutin.
• Filgrastim (G-CSF).
• p24 vaccine.
• Patients must have:
• Diagnosis of AIDS by CDC criteria.
• Diagnosis of peripheral (not immediately sight-threatening) CMV retinitis.
• Visual acuity in the affected eye of >= three lines on the ETDRS (Early Treatment Diabetic Retinopathy Study) chart at 1 m distance.
• Life expectancy of at least 3 months.
• Consent of parent or guardian in patients less than 18 years of age.
• Prior Medication:
• Allowed:
• Acyclovir.
• Prior ganciclovir, foscarnet, or CMV hyperimmune immunoglobulin if given solely as prophylaxis.

You may not qualify if…

• Co-existing Condition:
• Patients with the following symptoms or conditions are excluded:
• Media opacity that precludes visualization of the fundus of both eyes.
• Retinal detachment.
• Clinically significant cardiac disease, including symptoms of ischemia, congestive heart failure, or arrhythmia.
• Active medical problems considered sufficient to hinder study compliance.
• Known clinically significant allergy to probenecid.
• Concurrent Medication:
• Excluded:
• Acyclovir (may be reinstituted following development of herpetic lesions).
• Ganciclovir.
• Foscarnet.
• Amphotericin B.
• Diuretics.
• Aminoglycoside antibiotics.
• CMV hyperimmune immunoglobulin.
• Intravenous pentamidine.
• Other nephrotoxic agents.
• Other investigational drugs with potential nephrotoxicity.
• Prior Medication:
• Excluded:
• Prior ganciclovir, foscarnet, or CMV hyperimmune immunoglobulin as therapy for CMV disease (although permitted if previously received solely as prophylaxis).
• Excluded within 1 week prior to study entry:
• Amphotericin B.
• Vidarabine.

Where it is running

• Los Angeles County - USC Med Ctr — Los Angeles, California, United States
• UCI Med Ctr — Orange, California, United States
• Mount Zion Med Ctr — San Francisco, California, United States
• Beth Israel Hosp — Boston, Massachusetts, United States
• Besselaar Associates — Princeton, New Jersey, United States
• Univ of Rochester Med Ctr — Rochester, New York, United States
• Univ of North Carolina Hosps — Chapel Hill, North Carolina, United States
• Audie L Murphy Veterans Administration Hosp — San Antonio, Texas, United States
• Charing Cross and Westminster Med School — London Southwest 10, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.